New England Journal of Medicine
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
2023 · DOI: 10.1056/NEJMoa2301972 · PMID: 37366315
View Source ↗
Researcher attestation
AeroPeptides supplies research-grade peptides for in-vitro and laboratory use only. Not for human or veterinary consumption.
By entering you confirm that:
Acceptance stored locally for 180 days.
Free domestic shipping on all orders over $150

Metabolics & Appetite
Retatrutide is an investigational 39-amino-acid triple agonist of the GIP, GLP-1, and glucagon receptors. Phase 2 clinical literature has characterised its receptor pharmacology and effects in obesity and metabolic dysfunction-associated steatotic liver disease research. For laboratory and research use only.
Third party tested
Certificate of Analysis — GLP3 – Reta (10-20mg)
Per-lot identity, purity, and endotoxin results are released as PDFs. Leave your email and we'll send the latest COA for this compound directly to your inbox.
Each lot is independently tested for identity, purity, and endotoxin. Full COA PDFs with HPLC traces and mass-spec spectra are available on request.
Research focus
Summary of contexts in which this compound appears in the preclinical literature. See cited studies for primary sources.
Retatrutide is an investigational 39-amino-acid triple agonist of the GIP, GLP-1, and glucagon receptors. Phase 2 clinical literature has characterised its receptor pharmacology and effects in obesity and metabolic dysfunction-associated steatotic liver disease research. For laboratory and research use only.
Technical specifications
Compound Information
Triple receptor agonist GIP/GLP-1/Glucagon (39 amino acids)
Storage & Stability
Lyophilized (powder)
-20°C • long-term stable in sealed lyophilized form
Reconstituted
2-8°C • use within 30 days of reconstitution
Light
Protect from light during storage and reconstitution
Room temperature
Short-term tolerant during shipping; minimise extended exposure above 25°C
Sources & references
New England Journal of Medicine
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
2023 · DOI: 10.1056/NEJMoa2301972 · PMID: 37366315
View Source ↗Nature Medicine
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Sanyal AJ, Kaplan LM, Frias JP, et al.
2024 · DOI: 10.1038/s41591-024-03018-2 · PMID: 38858523
View Source ↗European Journal of Clinical Pharmacology
A review of an investigational drug retatrutide, a novel triple agonist agent for obesity treatment
Kaur M, Misra S
2024 · DOI: 10.1007/s00228-024-03646-0 · PMID: 38367045
View Source ↗Cardiology in Review
The First Triple Agonist for Antiobesity: Retatrutide
Tetelbaum L, Mullally JA, Frishman WH
2024 · DOI: 10.1097/CRD.0000000000000793 · PMID: 39724554
View Source ↗NPJ Metabolic Health and Disease
Incretin triple agonist retatrutide alleviates obesity-associated cancer progression
Marathe SJ, Grey EW, Bohm MS, et al.
2025 · DOI: 10.1038/s44324-025-00054-5 · PMID: 40094000
View Source ↗5 peer-reviewed references listed. Citations verified against NCBI PubMed records. For research and educational reference only — does not constitute medical advice.
Researcher FAQ
No. AeroPeptides materials are sold exclusively for in-vitro research and laboratory analytical use. They are not intended to diagnose, treat, cure, or prevent any disease, and are not approved for human or animal administration.
By placing an order, you confirm that you are a qualified researcher and that the material will be used in accordance with all applicable institutional and jurisdictional regulations.
Each lot is independently tested for identity, purity, and mass using HPLC and mass spectrometry. The COA lists the lot number, test date, assay results, and the laboratory that performed the analysis.
Public COA documents are being prepared. In the meantime, you can request a COA for your specific lot and we’ll email it within 1 business day.
Orders ship within 1 business day from the US. Lyophilized peptides are shipped with insulation appropriate to season; short-term ambient excursions during transit do not measurably affect potency.
On receipt, store at −20°C in the sealed vial until reconstitution. See the handling matrix for full storage parameters. Tracked shipping is included; we ship to all US states and most international destinations.
Most peptides are reconstituted with bacteriostatic water (BAC). The volume depends on the target working concentration. Use our Peptide Calculator to compute volume, U-100 insulin syringe units, and doses per vial from peptide mass and target dose.
Once reconstituted, store at 2–8°C and use within 30 days. Protect the vial from light during storage and handling.
Because peptides are temperature-sensitive research materials, we cannot accept returns of opened or unsealed vials. If a shipment arrives damaged or the seal is broken on arrival, contact us within 7 days and we’ll replace or refund.
See our full returns policy for details.
Don’t see your question? Contact our research team — we typically reply within one business day.
In the same category
⚠ Important research notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.